Top

Published in:

01-02-2019 | Review Article

Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma

Authors: Fang-Tian Wu, Luo Lu, Wei Xu, Jian-Yong Li

Published in: Annals of Hematology | Issue 2/2019

Abstract

Diffuse large B cell lymphoma (DLBCL), the most common non-Hodgkin lymphoma (NHL), is a clinically and molecularly heterogeneous malignant lymphoproliferative disease. In the era of personalized medicine, genetic information is critical to early diagnosis, aiding risk stratification, directing therapeutic option, and monitoring disease relapse. However, lacking a circulating disease with most DLBCL cases hampers the acquisition of tumor genomic landscapes and disease dynamics. Circulating tumor DNA (ctDNA) is a novel noninvasive, real-time, and tumor-specific biomarker, reliably reflecting the comprehensive tumor genetic profiles, thus holds great promise in individualized medicine, including precise diagnosis and prognosis, response monitoring, and relapse detection of DLBCL. Here, we reviewed the recent advances of ctDNA in DLBCL and discussed its clinical values at different time points during the disease courses by comparing with the current routine methods in clinical practice. Collectively, we anticipated that ctDNA will ultimately be integrated into the management of DLBCL to facilitate precision medicine.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. https://doi.org/10.1002/ijc.29210 CrossRefPubMed

Sehn LH, Gascoyne RD (2015) Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125(1):22–32. https://doi.org/10.1182/blood-2014-05-577189 CrossRefPubMed

Larouche JF, Berger F, Chassagne-Clement C et al (2010) Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol 28(12):2094–2100. https://doi.org/10.1200/JCO.2009.24.5860 CrossRefPubMed

Wan JC, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N (2017) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17(4):223–238. https://doi.org/10.1038/nrc.2017.7 CrossRefPubMed

Kristensen LS, Hansen JW, Kristensen SS, Tholstrup D, Harslof LB, Pedersen OB, De Nully Brown P, Gronbaek K (2016) Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. Clin Epigenetics 8(1):95. https://doi.org/10.1186/s13148-016-0261-y CrossRefPubMedPubMedCentral

Bohers E, Viailly PJ, Dubois S et al (2015) Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. Haematologica 100(7):e280–e284. https://doi.org/10.3324/haematol.2015.123612 CrossRefPubMedPubMedCentral

Ladetto M, Buske C, Hutchings M et al (2017) ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Ann Oncol 27(12):2149–2160. https://doi.org/10.1093/annonc/mdx061 CrossRef

Safar V, Dupuis J, Itti E et al (2012) Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 30(2):184–190. https://doi.org/10.1200/JCO.2011.38.2648 CrossRefPubMed

Zinzani PL, Broccoli A, Gioia DM et al (2016) Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol 34(12):1376–1385. https://doi.org/10.1200/JCO.2015.63.0699 CrossRefPubMed

10.

Johnson P, Federico M, Kirkwood A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 374(25):2419–2429. https://doi.org/10.1056/NEJMoa1510093 CrossRefPubMedPubMedCentral

11.

Moskowitz CH, Schoder H, Teruya-Feldstein J et al (2010) Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol 28(11):1896–1903. https://doi.org/10.1200/JCO.2009.26.5942 CrossRefPubMedPubMedCentral

12.

Abel GA (2015) Does surveillance imaging after treatment for diffuse large B-cell lymphoma really work? J Clin Oncol 33(13):1427–1429. https://doi.org/10.1200/JCO.2014.60.1120 CrossRefPubMed

13.

Phillips T, Mercer J (2017) Surveillance scans in lymphoma: friend or foe? Curr Treat Options in Oncol 18(2):10. https://doi.org/10.1007/s11864-017-0451-7 CrossRef

14.

Pitini V, Arrigo C, Di Mirto C, Garufi L, Mondello P, d’Aquino A, Altavilla G (2015) Should the use of surveillance imaging in diffuse large B-cell lymphoma be discontinued? J Clin Oncol 33(14):1623. https://doi.org/10.1200/JCO.2014.60.0627 CrossRefPubMed

15.

Mamot C, Klingbiel D, Hitz F et al (2015) Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol 33(23):2523–2529. https://doi.org/10.1200/JCO.2014.58.9846 CrossRefPubMed

16.

El-Galaly TC, Jakobsen LH, Hutchings M et al (2015) Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study. J Clin Oncol 33(34):3993–3998. https://doi.org/10.1200/JCO.2015.62.0229 CrossRefPubMed

17.

Wilson WH, Young RM, Schmitz R et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21(8):922–926. https://doi.org/10.1038/nm.3884 CrossRefPubMedPubMedCentral

18.

Davids MS, Roberts AW, Seymour JF et al (2017) Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 35(8):826–833. https://doi.org/10.1200/JCO.2016.70.4320 CrossRefPubMedPubMedCentral

19.

Roschewski M, Staudt LM, Wilson WH (2014) Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 11(1):12–23. https://doi.org/10.1038/nrclinonc.2013.197 CrossRefPubMed

20.

Assouline SE, Nielsen TH, Yu S et al (2016) Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood 128(2):185–194. https://doi.org/10.1182/blood-2016-02-699520 CrossRefPubMedPubMedCentral

21.

Ennishi D, Mottok A, Ben-Neriah S et al (2017) Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell of origin-specific clinical impact. Blood. https://doi.org/10.1182/blood-2016-11-747022

22.

Chapuy B, Cheng H, Watahiki A et al (2016) Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood 127(18):2203–2213. https://doi.org/10.1182/blood-2015-09-672352 CrossRefPubMedPubMedCentral

23.

Morin RD, Assouline S, Alcaide M et al (2016) Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin Cancer Res 22(9):2290–2300. https://doi.org/10.1158/1078-0432.CCR-15-2123 CrossRefPubMed

24.

Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J (2016) Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164(1–2):57–68. https://doi.org/10.1016/j.cell.2015.11.050 CrossRefPubMedPubMedCentral

25.

Camus V, Jardin F, Tilly H (2017) The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential. Expert Rev Mol Diagn 17(6):557–566. https://doi.org/10.1080/14737159.2017.1319765 CrossRefPubMed

26.

Mandel P, Metais P (1948) Les acides nucléiques du plasma sanguin chez l’homme. C R Seances Soc Biol Fil 142(3–4):241–243PubMed

27.

Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37(3):646–650PubMed

28.

Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M (1989) Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46(5):318–322CrossRefPubMed

29.

Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL (1994) Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomark Prev 3(1):67–71

30.

Diehl F, Li M, Dressman D et al (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102(45):16368–16373. https://doi.org/10.1073/pnas.0507904102 CrossRefPubMedPubMedCentral

31.

Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14(9):985–990. https://doi.org/10.1038/nm.1789 CrossRefPubMed

32.

Forshew T, Murtaza M, Parkinson C et al (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4(136):136ra168. https://doi.org/10.1126/scitranslmed.3003726 CrossRef

33.

Newman AM, Bratman SV, To J et al (2014) An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20(5):548–554. https://doi.org/10.1038/nm.3519 CrossRefPubMedPubMedCentral

34.

Frickhofen N, Muller E, Sandherr M, Binder T, Bangerter M, Wiest C, Enz M, Heimpel H (1997) Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with B-cell neoplasia. Blood 90(12):4953–4960PubMed

35.

Deligezer U, Yaman F, Erten N, Dalay N (2003) Frequent copresence of methylated DNA and fragmented nucleosomal DNA in plasma of lymphoma patients. Clin Chim Acta 335(1–2):89–94. https://doi.org/10.1016/s0009-8981(03)00279-1 CrossRefPubMed

36.

Shi H, Guo J, Duff DJ et al (2007) Discovery of novel epigenetic markers in non-Hodgkin’s lymphoma. Carcinogenesis 28(1):60–70. https://doi.org/10.1093/carcin/bgl092 CrossRefPubMed

37.

He J, Wu J, Jiao Y, Wagner-Johnston N, Ambinder RF, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N (2011) IgH gene rearrangements as plasma biomarkers in Non- Hodgkin’s lymphoma patients. Oncotarget 2(3):178–185. https://doi.org/10.18632/oncotarget.235 CrossRefPubMedPubMedCentral

38.

Roschewski M, Dunleavy K, Pittaluga S et al (2015) Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 16(5):541–549. https://doi.org/10.1016/s1470-2045(15)70106-3 CrossRefPubMedPubMedCentral

39.

Scherer F, Kurtz DM, Newman AM et al (2016) Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med 8(364):364ra155. https://doi.org/10.1126/scitranslmed.aai8545 CrossRefPubMedPubMedCentral

40.

Kurtz DM, Green MR, Bratman SV et al (2015) Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 125(24):3679–3687. https://doi.org/10.1182/blood-2015-03-635169 CrossRefPubMedPubMedCentral

41.

Yeh P, Hunter T, Sinha D et al (2017) Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. Nat Commun 8:14756. https://doi.org/10.1038/ncomms14756 CrossRefPubMedPubMedCentral

42.

Sarkozy C, Huet S, Carlton VE et al (2017) The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget 8(5):8765–8774. https://doi.org/10.18632/oncotarget.14448 CrossRefPubMedPubMedCentral

43.

Camus V, Sarafan-Vasseur N, Bohers E et al (2016) Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma 57(9):2171–2179. https://doi.org/10.3109/10428194.2016.1139703 CrossRefPubMed

44.

Camus V, Stamatoullas A, Mareschal S et al (2016) Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica 101(9):1094–1101. https://doi.org/10.3324/haematol.2016.145102 CrossRefPubMedPubMedCentral

45.

Alcaide M, Yu S, Bushell K et al (2016) Multiplex droplet digital PCR quantification of recurrent somatic mutations in diffuse large B-cell and follicular lymphoma. Clin Chem 62(9):1238–1247. https://doi.org/10.1373/clinchem.2016.255315 CrossRefPubMed

46.

Wedge E, Hansen JW, Garde C et al (2017) Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma. Am J Hematol. https://doi.org/10.1002/ajh.24751

47.

Sun K, Jiang P, Chan KC et al (2015) Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A 112(40):E5503–E5512. https://doi.org/10.1073/pnas.1508736112 CrossRefPubMedPubMedCentral

48.

Chabon JJ, Simmons AD, Lovejoy AF et al (2016) Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815. https://doi.org/10.1038/ncomms11815 CrossRefPubMedPubMedCentral

49.

De Mattos-Arruda L, Mayor R, Ng CK et al (2015) Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6:8839. https://doi.org/10.1038/ncomms9839 CrossRefPubMedPubMedCentral

50.

Wang Y, Springer S, Zhang M et al (2015) Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A 112(31):9704–9709. https://doi.org/10.1073/pnas.1511694112 CrossRefPubMedPubMedCentral

51.

Sriram KB, Relan V, Clarke BE et al (2012) Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas. BMC Cancer 12(1). https://doi.org/10.1186/1471-2407-12-428

52.

Birkenkamp-Demtroder K, Nordentoft I, Christensen E et al (2016) Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol 70(1):75–82. https://doi.org/10.1016/j.eururo.2016.01.007 CrossRefPubMed

53.

Jiang P, Chan CW, Chan KC et al (2015) Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A 112(11):E1317–E1325. https://doi.org/10.1073/pnas.1500076112 CrossRefPubMedPubMedCentral

54.

Underhill HR, Kitzman JO, Hellwig S et al (2016) Fragment length of circulating tumor DNA. PLoS Genet 12(7):e1006162. https://doi.org/10.1371/journal.pgen.1006162 CrossRefPubMedPubMedCentral

55.

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61(4):1659–1665PubMed

56.

Fleischhacker M, Schmidt B (2007) Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta 1775(1):181–232. https://doi.org/10.1016/j.bbcan.2006.10.001 CrossRefPubMed

57.

Sunami E, Vu AT, Nguyen SL, Giuliano AE, Hoon DS (2008) Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann N Y Acad Sci 1137:171–174. https://doi.org/10.1196/annals.1448.011 CrossRefPubMed

58.

De Vlaminck I, Martin L, Kertesz M et al (2015) Noninvasive monitoring of infection and rejection after lung transplantation. Proc Natl Acad Sci U S A 112(43):13336–13341. https://doi.org/10.1073/pnas.1517494112 CrossRefPubMedPubMedCentral

59.

Rossi D, Diop F, Spaccarotella E et al (2017) Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood 129(14):1947–1957. https://doi.org/10.1182/blood-2016-05-719641 CrossRefPubMed

60.

Armand P, Oki Y, Neuberg DS et al (2013) Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 163(1):123–126. https://doi.org/10.1111/bjh.12439 CrossRefPubMed

61.

Herrera AF, Kim HT, Kong KA et al (2016) Next-generation sequencing-based detection of circulating tumour DNA after allogeneic stem cell transplantation for lymphoma. Br J Haematol 175(5):841–850. https://doi.org/10.1111/bjh.14311 CrossRefPubMedPubMedCentral

62.

Hohaus S, Giachelia M, Massini G et al (2009) Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Oncol 20(8):1408–1413. https://doi.org/10.1093/annonc/mdp006 CrossRefPubMed

63.

Barault L, Amatu A, Bleeker FE et al (2015) Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann Oncol 26(9):1994–1999. https://doi.org/10.1093/annonc/mdv272 CrossRefPubMed

64.

Bedin C, Enzo MV, Del Bianco P, Pucciarelli S, Nitti D, Agostini M (2017) Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. Int J Cancer 140(8):1888–1898. https://doi.org/10.1002/ijc.30565 CrossRefPubMed

65.

Chi KR (2016) The tumour trail left in blood. Nature 532(7598):269–271. https://doi.org/10.1038/532269a CrossRefPubMed

66.

Yuan C, Clish CB, Wu C et al (2016) Circulating metabolites and survival among patients with pancreatic cancer. J Natl Cancer Inst 108(6):djv409. https://doi.org/10.1093/jnci/djv409 CrossRefPubMedPubMedCentral

67.

Perdigones N, Murtaza M (2017) Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis. Pharmacol Ther. https://doi.org/10.1016/j.pharmthera.2017.02.003

68.

Murtaza M, Dawson SJ, Tsui DW et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497(7447):108–112. https://doi.org/10.1038/nature12065 CrossRefPubMed

69.

Bettegowda C, Sausen M, Leary RJ et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6(224):224ra224. https://doi.org/10.1126/scitranslmed.3007094 CrossRef

70.

Gormally E, Vineis P, Matullo G et al (2006) TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res 66(13):6871–6876. https://doi.org/10.1158/0008-5472.CAN-05-4556 CrossRefPubMed

71.

McMullen JRW, Selleck M, Wall NR, Senthil M (2017) Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy. Oncotarget. https://doi.org/10.18632/oncotarget.16480

72.

Vidal J, Muinelo L, Dalmases A et al (2017) Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. https://doi.org/10.1093/annonc/mdx125

73.

Guo S, Diep D, Plongthongkum N, Fung HL, Zhang K, Zhang K (2017) Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat Genet 49(4):635–642. https://doi.org/10.1038/ng.3805 CrossRefPubMedPubMedCentral

74.

Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL (2017) Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol 35(12):1274–1280. https://doi.org/10.1200/JCO.2016.70.4627 CrossRefPubMed

75.

Camus V, Miloudi H, Taly A, Sola B, Jardin F (2017) XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J Hematol Oncol 10(1):47. https://doi.org/10.1186/s13045-017-0412-4 CrossRefPubMedPubMedCentral

76.

Dubois S, Mareschal S, Picquenot JM et al (2015) Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget 6(18):16712–16724. https://doi.org/10.18632/oncotarget.3154 CrossRefPubMedPubMedCentral

77.

Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, Meldgaard P (2014) Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 120(24):3896–3901. https://doi.org/10.1002/cncr.28964 CrossRefPubMed

78.

Oxnard GR, Paweletz CP, Kuang Y et al (2014) Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20(6):1698–1705. https://doi.org/10.1158/1078-0432.CCR-13-2482 CrossRefPubMedPubMedCentral

79.

Morelli MP, Overman MJ, Dasari A et al (2015) Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731–736. https://doi.org/10.1093/annonc/mdv005 CrossRefPubMedPubMedCentral

80.

Kridel R, Sehn LH, Gascoyne RD (2017) Can histologic transformation of follicular lymphoma be predicted and prevented? Blood. https://doi.org/10.1182/blood-2017-03-691345

81.

Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068. https://doi.org/10.1200/JCO.2013.54.8800 CrossRefPubMedPubMedCentral

82.

Adams HJ, Nievelstein RA, Kwee TC (2015) Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. Br J Haematol 170(2):185–191. https://doi.org/10.1111/bjh.13420 CrossRefPubMed

83.

Kwok M, Wu SP, Mo C, Summers T, Roschewski M (2016) Circulating tumor DNA to monitor therapy for aggressive B-cell lymphomas. Curr Treat Options in Oncol 17(9):47. https://doi.org/10.1007/s11864-016-0425-1 CrossRef

84.

Luminari S, Galimberti S, Versari A et al (2016) Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Haematologica 101(2):e66–e68. https://doi.org/10.3324/haematol.2015.132811 CrossRefPubMedPubMedCentral

85.

Cheminant M, Derrieux C, Touzart A et al (2016) Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica 101(3):336–345. https://doi.org/10.3324/haematol.2015.134957 CrossRefPubMedPubMedCentral

86.

Thompson PA, Wierda WG (2016) Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood 127(3):279–286. https://doi.org/10.1182/blood-2015-08-634816 CrossRefPubMedPubMedCentral

87.

Garcia-Murillas I, Schiavon G, Weigelt B et al (2015) Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 7(302):302ra133. https://doi.org/10.1126/scitranslmed.aab0021 CrossRefPubMed

88.

Tie J, Wang Y, Tomasetti C et al (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8(346):346ra392. https://doi.org/10.1126/scitranslmed.aaf6219 CrossRef

89.

Cohen JB, Behera M, Thompson CA, Flowers CR (2017) Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. Blood 129(5):561–564. https://doi.org/10.1182/blood-2016-08-685073 CrossRefPubMedPubMedCentral

90.

Armitage JO, Vose JM (2015) To surveil or not to surveil. J Clin Oncol 33(34):3983–3984. https://doi.org/10.1200/JCO.2015.63.5946 CrossRefPubMed

91.

Nabhan C, Smith SM, Cifu AS (2016) Surveillance imaging in patients in remission from Hodgkin and diffuse large B-cell lymphoma. JAMA 315(19):2115–2116. https://doi.org/10.1001/jama.2016.4913 CrossRefPubMed

92.

Siravegna G, Marsoni S, Siena S, Bardelli A (2017) Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. https://doi.org/10.1038/nrclinonc.2017.14

93.

Malentacchi F, Pizzamiglio S, Verderio P, Pazzagli M, Orlando C, Ciniselli CM, Gunther K, Gelmini S (2015) Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplas external quality assessment experience. Clin Chem Lab Med 53(12):1935–1942. https://doi.org/10.1515/cclm-2014-1161 CrossRefPubMed

94.

Parpart-Li S, Bartlett B, Popoli M et al (2016) The effect of preservative and temperature on the analysis of circulating tumor DNA. Clin Cancer Res 23(10):2471–2477. https://doi.org/10.1158/1078-0432.CCR-16-1691 CrossRefPubMed

95.

El Messaoudi S, Rolet F, Mouliere F, Thierry AR (2013) Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 424:222–230. https://doi.org/10.1016/j.cca.2013.05.022 CrossRefPubMed

96.

Devonshire AS, Whale AS, Gutteridge A, Jones G, Cowen S, Foy CA, Huggett JF (2014) Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem 406(26):6499–6512. https://doi.org/10.1007/s00216-014-7835-3 CrossRefPubMedPubMedCentral

97.

Vandenberghe P, Wlodarska I, Tousseyn T et al (2015) Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin’s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol 2(2):e55–e65. https://doi.org/10.1016/s2352-3026(14)00039-8 CrossRefPubMed

Title: Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma
Authors: Fang-Tian Wu
Luo Lu
Wei Xu
Jian-Yong Li
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 2/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3529-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Prognostic impact of skeletal muscle assessed by computed tomography in patients with acute myeloid leukemia

Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review

Epidemiological, clinical and genetic characterization of aplastic anemia patients in Pakistan

Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma

Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment

Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage